About Us
2006 Channel Biomedical Group
Established in 2006, Channel InnoMatrix began as a consulting firm with a single focus: helping innovative medical, biotech, and pharmaceutical companies bring their ideas and technologies into international markets. Over the years, we built expertise in cross-continental commercialization, distribution strategy, and business-to-business channel development, creating bridges between Europe, Asia, and North America.
2012 Channel Biomedical Group
In 2012, this foundation evolved into the Channel Biomedical Group, expanding our reach with new operations in Hong Kong and Sweden. Today, the Group integrates three main activities:
For more details on our biomedical consulting expertise, please also visit our sister company website at www.channelbiomedix.com.
Established in 2006, Channel InnoMatrix began as a consulting firm with a single focus: helping innovative medical, biotech, and pharmaceutical companies bring their ideas and technologies into international markets. Over the years, we built expertise in cross-continental commercialization, distribution strategy, and business-to-business channel development, creating bridges between Europe, Asia, and North America.
2012 Channel Biomedical Group
In 2012, this foundation evolved into the Channel Biomedical Group, expanding our reach with new operations in Hong Kong and Sweden. Today, the Group integrates three main activities:
- Consulting and Business Development: Strategic support for innovation-driven companies, including partnerships and interim management.
- Product Distribution and Commercialization: Dedicated channels for medical, biotech, and wellness products.
- Innovation and Investment: Collaboration with startups, particularly in the Nordic region, and co-development of new health concepts.
For more details on our biomedical consulting expertise, please also visit our sister company website at www.channelbiomedix.com.
Expertise
Channel Innomatrix, a company of Channel Biomedical Group, comprises a formidable combination of extensive commercial experience and international footsteps in the biomedical industry with medical, business, legal and linguistic education. Our experience ranges from fostering innovative technology to re-position mature products; from technology licensing to establish international product distribution network; from direct selling and marketing to scientific lecturing at world congresses; from consolidating international market to opening up emerging markets in the Asia Pacific region.
Jibin Chi, MBA, MBI, MD
Managing Director
Dr. Chi is an accomplished international commercial expert, scientific lecturer, medical doctor, and entrepreneur whose career spans over three decades across China, Japan, Australia, the Netherlands, Germany, Switzerland, the United States, and Sweden. With a unique integration of medical, scientific, and international business expertise, he has cultivated parallel yet interconnected strengths—leading the commercialization of cutting-edge technologies as a business executive while simultaneously advancing science as a recognized academic speaker.
As a recognized thought leader in translational medicine, Dr. Chi has developed a disruptive new theory on diabetes and brought forward a new unified disease development model. His work has been recognized by top scientists and clinicians; he has thus served as an invited scientific speaker at multiple international conferences. Moreover, he is a featured scientific lecturer, healing expert, and meditation instructor on the world’s biggest medical wellness cruise, “Holistic Holiday at Sea,” rated by National Geographic as one of the best luxury wellness holidays in the world. His lecture and workshop were accredited CME & CEU programs certified by the Medical University of Miami.
His contribution to the field of applied science in air, energy, breathing, and health has earned him the distinction of becoming the first recipient of the Art of Air Award in the category of science in 2018 and 2019.
Dr. Chi was honored with the prestigious Honorary Fellowship Award at the 15th World Congress in 2025, recognized as the most distinguished individual by the Association of DiabetesIndia.
Managing Director
Dr. Chi is an accomplished international commercial expert, scientific lecturer, medical doctor, and entrepreneur whose career spans over three decades across China, Japan, Australia, the Netherlands, Germany, Switzerland, the United States, and Sweden. With a unique integration of medical, scientific, and international business expertise, he has cultivated parallel yet interconnected strengths—leading the commercialization of cutting-edge technologies as a business executive while simultaneously advancing science as a recognized academic speaker.
As a recognized thought leader in translational medicine, Dr. Chi has developed a disruptive new theory on diabetes and brought forward a new unified disease development model. His work has been recognized by top scientists and clinicians; he has thus served as an invited scientific speaker at multiple international conferences. Moreover, he is a featured scientific lecturer, healing expert, and meditation instructor on the world’s biggest medical wellness cruise, “Holistic Holiday at Sea,” rated by National Geographic as one of the best luxury wellness holidays in the world. His lecture and workshop were accredited CME & CEU programs certified by the Medical University of Miami.
His contribution to the field of applied science in air, energy, breathing, and health has earned him the distinction of becoming the first recipient of the Art of Air Award in the category of science in 2018 and 2019.
Dr. Chi was honored with the prestigious Honorary Fellowship Award at the 15th World Congress in 2025, recognized as the most distinguished individual by the Association of DiabetesIndia.
|
|
Channel Biomedical GroupChannel Innomatrix BV
Deltahof 16 2181EN, Hillegom, the Netherlands Channel Biomedix Filal
Svinningeuddsvagen 74 18492, Akersberga, Sweden Channel Innomed Co. Ltd.
18th Floor, 128 Wellington Street Central, Hong Kong |